PRAX
NASDAQPraxis Precision Medicines Inc.
Price$333.30+0.72 (+0.21%)
01:30 PM07:45 PM
News · 26 weeks82+67%
2025-11-092026-05-03
Mix3090d
- Other13(43%)
- SEC Filings9(30%)
- Earnings2(7%)
- Insider2(7%)
- Offering2(7%)
- Analyst2(7%)
Latest news
25 items- SECSEC Form 10-Q filed by Praxis Precision Medicines Inc.10-Q - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsFDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026 EMBRAVE Part A study results showed elsunersen treatment led to a 77% placebo-adjusted reduction in monthly seizures and demonstrated disease-modifying improvements in patients with early-seizure onset SCN2A-DEE Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026 Recruiting completed for relutrigine EMERALD study in broad DEEs, with top
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- PRPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on May 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 5,420 shares of its common stock to twenty-one new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). Th
- PRPraxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor ConferenceBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and provide a corporate update before the financial markets open on Thursday, May 7, 2026. The Company will host a conference call and a live webcast to review the first quarter financial results and provide a corporate update on Thursday, May 7, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the Events & Presentations page of
- SECSEC Form DEFA14A filed by Praxis Precision Medicines Inc.DEFA14A - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECSEC Form DEF 14A filed by Praxis Precision Medicines Inc.DEF 14A - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorFDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 29, 2027 and is not planning to hold an advisory committee meeting. "Today's announcement brings us one st
- PRPraxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026Praxis to present 3 oral presentations and 12 posters at AAN 2026Visit Praxis at Booth #2324 for an in-booth speaker showcase featuring Phase 3 Essential3 results for ulixacaltamide, plus scientific exchange on essential tremor. BOSTON, April 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will present expanded analyses from the Phase 3 Essential3 p
- ANALYSTRaymond James initiated coverage on Praxis Precision Medicines with a new price targetRaymond James initiated coverage of Praxis Precision Medicines with a rating of Strong Buy and set a new price target of $815.00
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Other Events8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathyElsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed in the open-label extension for up to one year 100% of elsunersen patients - and none on placebo - had additional improvements, including sleep, motor function, muscle tone and attention No treatment-emergent or serious adverse events related to study drug reported BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced positive top
- PRPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on April 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,558 shares of its common stock to eighteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- PRPraxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEsFDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for relutrigine, for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of September 27, 2026. "Our first FDA acceptance of an NDA submission marks a significant milestone in our evolution
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- PRPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
- ANALYSTWolfe Research initiated coverage on Praxis Precision Medicines with a new price targetWolfe Research initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $500.00
- SECSEC Form S-8 filed by Praxis Precision Medicines Inc.S-8 - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECSEC Form 10-K filed by Praxis Precision Medicines Inc.10-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- SECPraxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
- PRPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsTwo new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of $926 million as of December 31, 2025 and net proceeds of $621 million from January 2026 public offering fund operations into 2028Conference call today, February 19, 2026 at 8:00 am E.T. BOSTON, Feb. 19, 2026 (GLOBE
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
- SECSEC Form SCHEDULE 13G filed by Praxis Precision Medicines Inc.SCHEDULE 13G - Praxis Precision Medicines, Inc. (0001689548) (Subject)
PRAX FAQ
7 questionsWhat does Praxis Precision Medicines Inc. do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562...Where does PRAX stock trade?
Praxis Precision Medicines Inc. (PRAX) is listed on NASDAQ.What sector and industry is PRAX in?
Praxis Precision Medicines Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Praxis Precision Medicines Inc. go public?
Praxis Precision Medicines Inc. (PRAX) completed its IPO in 2020.What are analysts saying about PRAX?
Praxis Precision Medicines Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy on 2026-04-10.What companies are similar to PRAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare PRAX side-by-side with any of them on Quantisnow.How can I track PRAX on Quantisnow?
Quantisnow aggregates Praxis Precision Medicines Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRAX to receive live email and push alerts on every new disclosure.